Latest filings (excl ownership)
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
7 Mar 24
S-8
Registration of securities for employees
9 Feb 24
S-8
Registration of securities for employees
9 Feb 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Alimera Appoints Maggie A. Pax to Its Board of Directors
8 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Alimera Sciences Reports Third Quarter 2023 Results
26 Oct 23
8-K
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
3 Oct 23
8-K
Unregistered Sales of Equity Securities
15 Aug 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Alimera Sciences Reports Second Quarter 2023 Results
10 Aug 23
8-K
Unregistered Sales of Equity Securities
2 Aug 23
424B3
Prospectus supplement
1 Aug 23
424B3
Prospectus supplement
12 Jul 23
EFFECT
Notice of effectiveness
12 Jul 23
CORRESP
Correspondence with SEC
10 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
S-3
Shelf registration
30 Jun 23
DEF 14A
Definitive proxy
29 Jun 23
8-K
Departure of Directors or Certain Officers
29 Jun 23
PRE 14A
Preliminary proxy
15 Jun 23
8-K
Other Events
9 Jun 23
D/A
$81.00 mm in equity / options / securities to be acquired, sold $81.00 mm, 16 investors
31 May 23
8-K
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
18 May 23
8-K
Alimera Sciences Reports First Quarter 2023 Results
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
S-8
Registration of securities for employees
28 Apr 23
D
$27.00 mm in equity / options / securities to be acquired, sold $12.00 mm, 4 investors
7 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Alimera Sciences Announces 2022 Financial Results and Business Update
31 Mar 23
DEFA14A
Additional proxy soliciting materials
27 Mar 23
8-K
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
27 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
1 Mar 23
Latest ownership filings
4
Philip Ashman
2 Apr 24
4
Jason M. Werner
13 Mar 24
4
Todd Michael Wood
13 Mar 24
4
RICHARD S EISWIRTH JR
13 Mar 24
4
Philip Ashman
13 Mar 24
4
Elliot Maltz
13 Mar 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
BOOTHBAY FUND MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
SC 13G/A
Altium Capital Management LP
13 Feb 24
4
Philip Ashman
11 Jan 24
4
Elliot Maltz
4 Jan 24
3
Elliot Maltz
4 Jan 24
4
Todd Michael Wood
13 Dec 23
3
Todd Michael Wood
13 Dec 23
SC 13G/A
MORGAN STANLEY
8 Dec 23
4
RUSSELL SKIBSTED
28 Nov 23
4
David Holland
28 Nov 23
4
Philip Ashman
28 Nov 23
4
Margaret Pax
8 Nov 23
3
Margaret Pax
8 Nov 23
4
BALAJI VENKATARAMAN
4 Oct 23
4
Ross D DeMont
4 Oct 23
4
Erin Parsons
4 Oct 23
4
Peter J. Pizzo III
4 Oct 23
4
Jason M. Werner
4 Oct 23
4
John Snisarenko
4 Oct 23
4
Michael Kaseta
4 Oct 23
4
RICHARD S EISWIRTH JR
4 Oct 23
4
DAVID EDWARD JOHNSON
15 Sep 23
SC 13G
Altium Capital Management LP
23 Aug 23
4
BALAJI VENKATARAMAN
17 Aug 23
4
DAVID EDWARD JOHNSON
17 Aug 23
SC 13D/A
Velan Capital Investment Management LP
16 Aug 23
SC 13G
LYTTON LAURENCE W
14 Aug 23
3
DAVID EDWARD JOHNSON
11 Aug 23
SC 13G
Stonepine Capital Management, LLC
10 Aug 23
SC 13G
BOOTHBAY FUND MANAGEMENT, LLC
10 Aug 23
SC 13D/A
Caligan Partners LP
3 Aug 23